As a result of the filing made with and declared effective by the SEC onApril 8, 2007, selling shareholders named in the prospectus may againcommence sales in accordance with the prospectus.

This notice is provided for informational purposes only, and does notrepresent a solicitation or offer to buy or sell any security. Any offerwill be made by means of a current prospectus only. This press releaseshall not constitute an offer to sell or a solicitation of an offer to buy,nor shall there be any sales of these securities in any state orjurisdiction in which such an offer, solicitation or sale would be unlawfulprior to registration or qualification under the securities laws of anysuch state or jurisdiction.

About RxElite, Inc.

RxElite, Inc. develops, manufactures, and markets generic prescription drugproducts in specialty generic markets. These markets include products inthe areas of anesthesia, sterile liquid dose drugs (including respiratoryinhalation drugs, ophthalmics, and injectable drugs), complex activepharmaceutical ingredients, and other specialty areas. www.RxElite.com

Safe Harbor Statement

This press release contains forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995 involving known andunknown risks, delays, and uncertainties that may cause our actual resultsor performance to differ materially from those expressed or implied bythese forward-looking statements. These risks, delays, and uncertaintiesinclude, but are not limited to: risks associated with the uncertainty offuture financial results, our reliance on our sole supplier, the limiteddiversification of our product offerings, additional financingrequirements, development of new products, government approval processes,the impact of competitive products or pricing, technological changes, theeffect of economic conditions and other uncertainties detailed in theCompany's filings with the Securities and Exchange Commission. The Companyundertakes no obligation to update any forward-looking statements.

For more information:Corporate InformationPh: (208) 288-5550Toll Free: (800) 414-1901Fax: (208) 288-1191Investor RelationsRic TenerPH: (208) 288-5550Fax: (208) 288-1191Email: Email Contact